Medically reviewed by Drugs.com. Last updated on May 24, 2022.
Commonly used brand name(s)
In the U.S.
- Prolia
- Xgeva
Available Dosage Forms:
- Solution
Therapeutic Class: Immunological Agent
Pharmacologic Class: Monoclonal Antibody
Uses for denosumab
Denosumab injection is used to treat osteoporosis (thinning of the bones) in women who have an increased risk for fractures after menopause, and osteoporosis in men. It is given when other medicines cannot be used or after other medicines did not work well. It is also used to treat osteoporosis in patients using steroid medicines for at least 6 months.
Denosumab injection is also used to treat bone loss in men with prostate cancer and women with breast cancer who are receiving cancer treatment.
It is used to prevent bone problems in patients with multiple myeloma and bone metastases (cancer that has spread) from tumors. Denosumab is also used to treat giant cell tumor of the bone that cannot be removed by surgery. Denosumab is also used to treat hypercalcemia of malignancy that has been treated with bisphosphonates (eg, alendronate, ibandronate, risedronate, Fosamax®) but did not work well.
Denosumab is to be given only by or under the supervision of your doctor.
Before using denosumab
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For denosumab, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to denosumab or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Use of denosumab injection is not recommended in the pediatric population, except for teenagers with giant cell tumor of the bone. The safety and efficacy of denosumab for other conditions have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limi...
